Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Candidate anti-herpesviral drugs; mechanisms of action and resistance.

Biron KK.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 68.

2.

Antiviral drugs for cytomegalovirus diseases.

Biron KK.

Antiviral Res. 2006 Sep;71(2-3):154-63. Epub 2006 May 23. Review.

PMID:
16765457
3.

Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.

Chou S, Marousek GI, Senters AE, Davis MG, Biron KK.

J Virol. 2004 Jul;78(13):7124-30.

4.

Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.

Kern ER, Hartline CB, Rybak RJ, Drach JC, Townsend LB, Biron KK, Bidanset DJ.

Antimicrob Agents Chemother. 2004 May;48(5):1749-55.

5.

Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus.

Underwood MR, Ferris RG, Selleseth DW, Davis MG, Drach JC, Townsend LB, Biron KK, Boyd FL.

Antimicrob Agents Chemother. 2004 May;48(5):1647-51.

6.

The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase.

Krosky PM, Baek MC, Jahng WJ, Barrera I, Harvey RJ, Biron KK, Coen DM, Sethna PB.

J Virol. 2003 Jul;77(14):7720-7.

7.

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER.

Antimicrob Agents Chemother. 2003 Jul;47(7):2186-92.

8.

Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

Selleseth DW, Talarico CL, Miller T, Lutz MW, Biron KK, Harvey RJ.

Antimicrob Agents Chemother. 2003 Apr;47(4):1468-71.

9.

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication.

Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, Drach JC, Biron KK.

Antimicrob Agents Chemother. 2002 Aug;46(8):2373-80.

10.

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW.

Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.

11.

Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.

Krosky PM, Borysko KZ, Nassiri MR, Devivar RV, Ptak RG, Davis MG, Biron KK, Townsend LB, Drach JC.

Antimicrob Agents Chemother. 2002 Feb;46(2):478-86.

12.

Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8.

Jabs DA, Martin BK, Forman MS, Dunn JP, Davis JL, Weinberg DV, Biron KK, Baldanti F, Hu H; Cytomegalovirus Retinitis and Viral Resistance Study Group.

Am J Ophthalmol. 2001 Nov;132(5):700-10.

PMID:
11704031
13.

Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.

McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK.

Clin Diagn Lab Immunol. 2001 Nov;8(6):1279-81.

14.

Differences in DNA packaging genes and sensitivity to benzimidazole ribonucleosides between human cytomegalovirus strains AD169 and Towne.

Krosky PM, Ptak RG, Underwood MR, Biron KK, Townsend LB, Drach JC.

Antivir Chem Chemother. 2000 Sep;11(5):349-52.

PMID:
11142634
15.

Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.

Jabs DA, Martin BK, Forman MS, Dunn JP, Davis JL, Weinberg DV, Biron KK, Baldanti F; Cytomegalovirus Retinitis and Viral Resistance Study Group.

J Infect Dis. 2001 Jan 15;183(2):333-337. Epub 2000 Dec 15.

PMID:
11120934
16.

Phosphorylation of ganciclovir phosphonate by cellular GMP kinase determines the stereoselectivity of anti-human cytomegalovirus activity.

Miller WH, Beauchamp LM, Meade E, Reardon JE, Biron KK, Smith AA, Goss CA, Miller RL.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):341-56.

PMID:
10772719
17.

Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94).

Chan JH, Chamberlain SD, Biron KK, Davis MG, Harvey RJ, Selleseth DW, Dornsife RE, Dark EH, Frick LW, Townsend LB, Drach JC, Koszalka GW.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):101-23. Erratum in: Nucleosides Nucleotides Nucleic Acids. 2002;21(1):109.

PMID:
10772705
19.

Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB.

Townsend LB, Gudmundsson KS, Daluge SM, Chen JJ, Zhu Z, Koszalka GW, Boyd L, Chamberlain SD, Freeman GA, Biron KK, Drach JC.

Nucleosides Nucleotides. 1999 Apr-May;18(4-5):509-19.

PMID:
10432642
20.

Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.

Talarico CL, Burnette TC, Miller WH, Smith SL, Davis MG, Stanat SC, Ng TI, He Z, Coen DM, Roizman B, Biron KK.

Antimicrob Agents Chemother. 1999 Aug;43(8):1941-6.

21.

Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient.

Baldanti F, Simoncini L, Talarico CL, Sarasini A, Biron KK, Gerna G.

AIDS. 1998 May 7;12(7):816-8. No abstract available.

PMID:
9619816
22.

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56.

Krosky PM, Underwood MR, Turk SR, Feng KW, Jain RK, Ptak RG, Westerman AC, Biron KK, Townsend LB, Drach JC.

J Virol. 1998 Jun;72(6):4721-8.

23.

The Cys607-->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients.

Baldanti F, Underwood MR, Talarico CL, Simoncini L, Sarasini A, Biron KK, Gerna G.

Antimicrob Agents Chemother. 1998 Feb;42(2):444-6.

24.

Interpreting human cytomegalovirus antiviral drug susceptibility testing: the role of mixed virus populations.

Baldanti F, Biron KK, Gerna G.

J Infect Dis. 1998 Mar;177(3):823-4. No abstract available.

PMID:
9498475
25.

Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product.

Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB, Biron KK.

J Virol. 1998 Jan;72(1):717-25.

26.

The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines.

He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DM.

J Virol. 1997 Jan;71(1):405-11.

28.

Cytomegalovirus: genetics of drug resistance.

Biron KK.

Adv Exp Med Biol. 1996;394:135-43. Review. No abstract available.

PMID:
8815680
29.

Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir.

Hanson MN, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A.

Antimicrob Agents Chemother. 1995 May;39(5):1204-5.

30.

Antiviral resistance in clinical practice.

Kimberlin DW, Crumpacker CS, Straus SE, Biron KK, Drew WL, Hayden FG, McKinlay M, Richman DD, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):423-38. Review. No abstract available.

PMID:
7574544
31.

Assays for antiviral drug resistance.

Kimberlin DW, Spector SA, Hill EL, Biron KK, Hay AJ, Mayers DL, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):403-13. Review. No abstract available.

PMID:
7574542
32.

Molecular mechanisms of antiviral resistance.

Kimberlin DW, Coen DM, Biron KK, Cohen JI, Lamb RA, McKinlay M, Emini EA, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):369-401. Review. No abstract available.

PMID:
7574541
33.

Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL, Stanat SC, Biron KK.

J Infect Dis. 1995 Mar;171(3):576-83.

PMID:
7876604
34.

A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate.

Baldanti F, Silini E, Sarasini A, Talarico CL, Stanat SC, Biron KK, Furione M, Bono F, Pal├╣ G, Gerna G.

J Virol. 1995 Feb;69(2):796-800.

35.
36.

Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.

Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH Jr.

J Infect Dis. 1994 Jul;170(1):68-75.

PMID:
8014522
37.

An enantiospecific synthesis of the human cytomegalovirus antiviral agent [(R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-4- hydroxybutyl]phosphonic acid.

Chamberlain SD, Biron KK, Dornsife RE, Averett DR, Beauchamp L, Koszalka GW.

J Med Chem. 1994 Apr 29;37(9):1371-7.

PMID:
8176714
38.

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Field AK, Biron KK.

Clin Microbiol Rev. 1994 Jan;7(1):1-13. Review.

40.

A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.

Sullivan V, Biron KK, Talarico C, Stanat SC, Davis M, Pozzi LM, Coen DM.

Antimicrob Agents Chemother. 1993 Jan;37(1):19-25.

41.

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells.

Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK.

Nature. 1992 Sep 3;359(6390):85. No abstract available.

PMID:
1326083
42.

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells.

Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK.

Nature. 1992 Jul 9;358(6382):162-4. Erratum in: Nature 1993 Dec 23-30;366(6457):756. Nature. 1992 Sep 3;359(6390):85.

PMID:
1319560
43.

Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.

Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK.

Antimicrob Agents Chemother. 1991 Nov;35(11):2191-7.

44.

Selective anabolism of 6-methoxypurine arabinoside in varicella-zoster virus-infected cells.

Biron KK, de Miranda P, Burnette TC, Krenitsky TA.

Antimicrob Agents Chemother. 1991 Oct;35(10):2116-20.

45.

Anabolic pathway of 6-methoxypurine arabinoside in cells infected with varicella-zoster virus.

de Miranda P, Burnette TC, Biron KK, Miller RL, Averett DR, Krenitsky TA.

Antimicrob Agents Chemother. 1991 Oct;35(10):2121-4.

46.

Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection.

Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J, Biron KK.

Ann Intern Med. 1991 Jul 1;115(1):19-21.

PMID:
1646585
47.

Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents.

Biron KK.

Transplant Proc. 1991 Jun;23(3 Suppl 3):162-7. Review. No abstract available.

PMID:
1648824
48.

Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy.

Linnemann CC Jr, Biron KK, Hoppenjans WG, Solinger AM.

AIDS. 1990 Jun;4(6):577-9.

PMID:
2167103
49.

Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS).

Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, Stanat SC, Biron KK.

Ann Intern Med. 1990 Feb 1;112(3):187-91.

PMID:
2297195
50.

Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients.

Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan MC.

N Engl J Med. 1989 Feb 2;320(5):289-93. No abstract available.

PMID:
2536135

Supplemental Content

Loading ...
Support Center